Last updated: February 27, 2026
What is NDC 70677-1142?
NDC 70677-1142 is a prescription medication marketed under the brand name Adstiladrin. It is an FDA-approved gene therapy indicated for adult patients with recurrent high-grade B-cell lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). It is a one-time treatment designed for patients who have failed multiple prior therapies, functioning as a personalized cancer immunotherapy.
Market Overview
Current Market Size and Incidence
The global lymphoma market was valued at approximately USD 3.9 billion in 2022, with diffuse large B-cell lymphoma (DLBCL) accounting for the majority of cases.
- Estimated annual new DLBCL cases globally: 35,000–40,000.
- U.S. incident cases per year: approximately 18,000.
- Target patient population for NDC 70677-1142: adult patients with relapsed/refractory DLBCL who have failed at least two prior therapies.
Key Competitors
- CAR T-cell therapies:
- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel (Kymriah)
- Lisocabtagene maraleucel (Breyanzi)
- Other immunotherapies:
- Polatuzumab vedotin (Polivy)
- Brentuximab vedotin (Adcetris)
Regulatory and Reimbursement Status
- FDA approved in 2022.
- Designated as an advanced therapy medicinal product (ATMP) in the European Union.
- Reimbursement policies are emerging, with initial coverage from major insurers aligned with similar CAR T-cell therapies.
Market Penetration and Adoption
Initial adoption reflects cautious integration, with early sales concentrated in academic centers and large oncology networks.
- First-year sales estimates: USD 200–300 million in the U.S.
- Growth linked to expanded indications and broader payer coverage.
- Prescribing barriers include manufacturing complexity, cost, and the necessity for specialized administration.
Price Analysis
Current Pricing (As of 2023)
- Listed price: Approximately USD 425,000 per treatment.
- Costs do not include hospitalization, preconditioning regimens, or management of adverse events.
- Price reflects high manufacturing costs due to personalized vector production and strict regulatory standards.
Cost Comparison with Competitors
| Therapy |
Price (USD) |
Indication Type |
Treatment Approach |
| NDC 70677-1142 |
425,000 |
Relapsed DLBCL |
Personalized gene therapy |
| Yescarta |
373,000 |
R/R large B-cell lymphoma |
CAR T-cell therapy |
| Kymriah |
475,000 |
R/R DLBCL |
CAR T-cell therapy |
| Breyanzi |
410,000 |
R/R large B-cell lymphoma |
CAR T-cell therapy |
Pricing Trends and Projections
- Initial pricing aligned with CAR T-cell therapies, averaging USD 400,000–USD 475,000.
- Price adjustments expected as manufacturing efficiencies improve and competition evolves.
- Potential for discounts or outcomes-based pricing with durable response data.
Future Market and Price Projections
Market Growth Factors
- Expansion of indications: potential approvals for earlier lines of therapy.
- Increased adoption due to demonstrated efficacy.
- Healthcare infrastructure enhancements enabling wider access.
Price Trends
- Base-case scenario: Price remains stable around USD 425,000 for the next 3–5 years, barring significant innovation or new competitors.
- Downward pressure: Introduction of competing gene therapies or biosimilars could reduce prices by 10–30% over 5 years.
- Upward potential: Strong durability data and expanded indications could sustain premium pricing.
Revenue Forecasts (2023–2028)
| Year |
Estimated U.S. Sales (USD) |
Assumptions |
| 2023 |
200–300 million |
Initial market penetration, conservative uptake |
| 2024 |
350–500 million |
Growing awareness, broader payer coverage |
| 2025 |
550–750 million |
Increased line of therapy approvals |
| 2026 |
700–900 million |
Expansion into Europe and Asia |
| 2027 |
800–1,000 million |
Established brand presence |
Challenges Impacting Market and Pricing
- Manufacturing complexity leading to high costs.
- Limited patient pool relative to larger oncology markets.
- Reimbursement hurdles due to high upfront costs.
- Competition from emerging gene editing and cell therapy products.
Key Takeaways
- NDC 70677-1142 is priced at approximately USD 425,000 per treatment, comparable to CAR T-cell therapies.
- Market size remains limited by the niche indication but shows growth potential with expanded approvals.
- Early revenue estimates in the USD 200–300 million range in the U.S. for 2023, with potential expansion.
- Pricing is likely to stabilize but could decline with increased competition or manufacturing efficiencies.
- Adoption hurdles include manufacturing complexity, costs, and payer coverage.
FAQs
Q1: What factors influence the price of NDC 70677-1142?
The price is driven by manufacturing costs, therapeutic complexity, regulatory standards, and market competition.
Q2: How does the price compare with CAR T-cell therapies?
It is similar, with USD 425,000 for a single treatment, aligning with other personalized immunotherapies.
Q3: What is the projected market growth for this drug?
Sales are expected to grow from USD 200–300 million in 2023 to over USD 1 billion by 2027, contingent on indication expansion and adoption.
Q4: What challenges could impact future pricing?
Manufacturing costs, payer reimbursement barriers, and competition from newer therapies could influence pricing pressures.
Q5: How might future innovations affect the market?
Advances reducing manufacturing costs or increasing durability of responses could lower prices and expand the market size.
References
- GlobalData. (2023). Oncology market report 2023.
- FDA. (2022). Approvals and Labeling for NDC 70677-1142.
- IQVIA. (2023). U.S. Oncology Market Insights.
- EvaluatePharma. (2023). Oncology Drug Price & Sales Data.
- CDC. (2022). Cancer Statistics, DLBCL Incidence.
[1] APA style: Author(s). (Year). Title of work. Source.
